Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
AbCellera Biologics Inc. (ABCL)
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 |
| | 10-K | 10-K | 10-K | 10-K | S-1 |
| Revenues | 100.0% | 100.0% | 100.0% | 100.0% | |
| Cost of goods sold | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross profit | 100.0% | 100.0% | 100.0% | 100.0% | |
| Sales and marketing | 2.3% | 1.8% | 1.6% | 10.9% | |
| Research and development | 22.2% | 16.5% | 12.6% | 87.1% | |
| General and administrative | 11.4% | 11.2% | 5.1% | 23.7% | |
| EBITDA | 50.3% | 62.2% | 69.0% | -21.6% | |
| Depreciation | 1.8% | 5.0% | 1.0% | 13.8% | |
| EBITA | 48.5% | 57.2% | 68.0% | -35.5% | |
| Amortization of intangibles | 3.9% | 2.7% | 1.1% | | |
| EBIT | 44.6% | 54.5% | 66.9% | -35.5% | |
| Pre-tax income | 49.3% | 58.4% | 67.7% | -19.0% | |
| Income taxes | 16.6% | 17.5% | 16.7% | 0.0% | |
| Net income | 32.7% | 40.9% | 51.0% | -19.0% | |
|